This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Wins Key European Protection for MS Pill Launch

Biogen Idec (BIIB - Get Report) cleared an important hurdle for the European launch of Tecfidera after regulators there decided Friday to grant market exclusivity to the multiple sclerosis pill. 

Tecfidera qualifies as a "new active substance," European regulators said, which along with patents, should give Biogen the market protection it needs to begin selling the drug in Europe later this year. 

Biogen had put the European launch of Tecfidera on hold while it worked to gain protection against the early entrance of cheaper generic copies. 

Biogen shares rose 9% to $275 in early Friday trading. 

J.P. Morgan biotech analyst Geoff Meacham reacted to the decision:

Must Read: Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

This morning, the CHMP granted Tecfidera regulatory data protection in EU, preventing generic competition for 10 years post launch. Tecfidera is now deemed a 'new active substance,' according to EU regulators. Recall, the CHMP recommended Tedfidera for approval in March, but Biogen delayed the launch to secure appropriate data exclusivity. While this process has been somewhat of a black box, Biogen has maintained it is entitled to regulatory data protection. We are not surprised by the favorable outcome and note that investor sentiment was leaning towards this outcome. This is implied by the fact that EU Tecfidera forecasts have not changed much despite the RDP uncertainty. That said, removal of the RDP overhang is a positive and paves the way for a 1H14 launch. While data protection is a clear positive, looking ahead we remain concerned about the potential for cannibalization in the MS business as well as further upside to WW Tecifera forecasts. As such, we are maintaining our Neutral rating.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $290.35 0.00%
AAPL $110.38 0.00%
FB $92.07 0.00%
GOOG $626.91 0.00%
TSLA $247.57 0.00%


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs